Transcriptomics

Dataset Information

43

Imatinib Treatment of GIST882


ABSTRACT: Gastrointestinal Stromal Tumor frequently harbor mutations in the KIT receptor tyrosine kinase and depend on its activity for growth. This underlies the efficacy of imatinib, a inhibitor of KIT activity, in GIST management. GIST882 is a patient derived GIST cell line that harbor a K640E exon 13 KIT mutation and is sensitive to imatinib treatment. To analyze the downstream effect of KIT inhibition, GIST882 cells were treated for 8 hours with 1μM Imatinib. Overall design: GIST882 cells were treated in triplicate with 0.1% DMSO or 1μM Imatinib for 8 hours. RNA was isolated and analyzed by Illumina Human HT-12 beadarray.

INSTRUMENT(S): Illumina HumanHT-12 V3.0 expression beadchip

ORGANISM(S): Homo sapiens  

SUBMITTER: Yu Chen  

PROVIDER: GSE22433 | GEO |

SECONDARY ACCESSION(S): PRJNA129059

REPOSITORIES: GEO

Similar Datasets

2010-10-13 | E-GEOD-22433 | ArrayExpress
2010-10-14 | E-GEOD-22852 | ArrayExpress
| GSE69465 | GEO
2008-12-24 | GSE8164 | GEO
2008-12-23 | E-GEOD-8164 | ArrayExpress
2015-01-08 | E-GEOD-64762 | ArrayExpress
| GSE63159 | GEO
2013-04-10 | E-GEOD-45901 | ArrayExpress
2015-08-01 | E-GEOD-63159 | ArrayExpress
2010-10-13 | E-GEOD-19396 | ArrayExpress